Haemonetics (NYSE: HAE) reported Q2 EPS of $0.60, $0.01 worse than the analyst estimate of $0.61. Revenue for the quarter came in at $239.9 million versus the consensus estimate of $239.99 million.

GUIDANCE:

Haemonetics sees FY2022 EPS of $2.40-$2.65, versus the consensus of $2.76.

For earnings history and earnings-related data on Haemonetics (HAE) click here.